{
	"l1liv0yeText": "Back",
	"l1liv0yfText": "Christensen MC et al. 2021<sup style=\"font-size:50%;\">1</sup>",
	"l1liv0yqText": "Brintellix® ",
	"l1liv0yrText": "10–20 mg/day (n=100)",
	"l1liv0ysText": "BRIN",
	"l1liv0ytText": "10 mg/",
	"l1liv0yuText": "day",
	"Brintellix_NewAss_7c6c3036c": "<span style=\"color: rgb(77, 127, 134); font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_NewAss_776fd33fe": "<font style=\"font-size: 15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>1.</b></font> <font style=\"font-size: 15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\"> Christensen MC et al. CNS Spectr. 2021 Oct 18;1-26. doi:10.1017/S1092852921000936. </font>",
	"Brintellix_NewAss_86c74166e": "<div style=\"color:#646162; font-size:21px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold';margin-bottom:20px;\">Brintellix<sup style=\"font-size:50%;\">®</sup> 20 mg in patients with major depressive disorder:<br>Updated analysis of efficacy, safety, and optimal timing of dose adjustment.</div>\n<div style=\"color:#646162; font-size:17px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';\">Analyses were based on six randomised, fixed-dosed studies and three flexible-dose<br>studies of patients with major depressive disorder (MDD):</div>",
	"Brintellix_NewAss_8c80b2bb8": "<div style=\"color:#e88200; font-size:12px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; margin-bottom:15px;\">6 short-term, fixed-dose studies:</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; margin-bottom:3px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Mahabledshwarkar AR et al. 2015a</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; margin-bottom:3px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Montgomery SA et al.2014</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; margin-bottom:3px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Jacobsen PL et al. 2015c</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; margin-bottom:3px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Mahableshwarkar AR et al. 2015b</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; margin-bottom:3px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> McIntyre RS et al. 2014</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; margin-bottom:3px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Nishimura A et al.2018</div>",
	"Brintellix_NewAss_85c88df21": "<div style=\"color:#e88200; font-size:12px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; margin-bottom:15px;\">3 short-term, flexible-dose studies:</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; margin-bottom:3px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Boulenger JP et al. 2014</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; margin-bottom:3px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Inoue T et al. 2020</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; margin-bottom:3px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Vieta E et al.2018</div>",
	"Brintellix_NewAss_837645c50": "<div style=\"color:#5f6a72; font-size:15px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; text-align:center;\">Placebo<br>(n=971 [FAS]; n=982 [SAS])</div>",
	"Brintellix_NewAss_8ff3674d7": "<div style=\"color:#5f6a72; font-size:15px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; text-align:center;\">Brintellix<sup style=\"font-size:50%;\">®</sup><br>(n=2061 [FAS]; n=2080 [SAS])</div>",
	"Brintellix_NewAss_8351820d6": "<div style=\"color:#5f6a72; font-size:15px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; text-align:center;\">Brintellix<sup style=\"font-size:50%;\">®</sup><br>(n=477)</div>",
	"Brintellix_NewAss_88bbdf94d": "<div style=\"color:#5f6a72; font-size:15px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; text-align:center;\">Mean change<br>from baseline to end<br>point in MADRS total<br>score and safety<br>analyses</div>",
	"Brintellix_NewAss_805dc0a68": "<div style=\"color:#5f6a72; font-size:15px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; text-align:center;\">Frequency<br>and timing of dose<br>adjustment</div>",
	"Brintellix_NewAss_8c3d6bd27": "<font style=\"color:#645e5e; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:11px;\">This analysis included six short-term (8-week), randomised, double-blind, placebo-controlled, fixed-dose studies which included Brintellix<sup style=\"font-size:50%;\">®</sup> 20 mg/day for the treatment<br>of MDD. In these fixed-dose studies, patients who were assigned to receive Brintellix<sup style=\"font-size:50%;\">®</sup> 20 mg/day received a 10 mg dose for the first week of the 8-week study.</font>",
	"Brintellix_NewAss_85bb6acbb": "<div style=\"color:#645e5e; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:11px; margin-bottom:10px;\">Frequency and timing of dose adjustment were examined from three short-term (8-week), randomised, controlled, flexible-dose studies in patients - including those<br>with partical response - receiving Brintellix<sup style=\"font-size:50%;\">®</sup> 10 mg/day for 1 week, followed by 10-20 mg/day (based on the treating physician’s clinical judgment) for at least 7 weeks.</div>\n<div style=\"color:#645e5e; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:11px; margin-bottom:10px;\">A separate dose adjustment analysis was also conducted using data from the COMPLETE study (Fagiolini A et al. 2021).</div>\n<div style=\"color:#645e5e; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:11px;\">FAS, full analysis set; SAS, safety analysis set.</div>"
}
